International Cancer Institute

Cancer Care, Research Training & Education

Home CMP ICI Multiple Myeloma Preceptorship

CMP ICI Multiple Myeloma Preceptorship

Multidisciplinary management, standards of care, optimal diagnostics, therapies, and future perspectives in the care of Multiple Myeloma patients in sub-Saharan Africa.

Eldoret, Kenya

 

Training Duration:  6 weeks

Course Director: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist Executive

Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com Website: www.intercancer.com

 

Course Coordination: Dr. Kevin Makori

Head, Office of Education and Training

International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email:  kevin.makori@intercancer.com Website: www.intercancer.com

 

This educational activity is provided independently by International Cancer Institute (ICI) through the Blueprint Program

 

ICI Education & Training Mission Statement

 

The ICI Preceptorship Program Mission is to measurably contribute to cancer patients’ safety and health outcomes and to support practice improvement by providing CME/CPD activities that enhance the ability of physicians and other healthcare team members to deliver quality and optimal healthcare services.

 

Purpose

The purpose of the ICI Preceptorship Program is to develop educational activities that clearly link the needs of the learner/participants with the planning process, format, and delivery of each activity, resulting in high-quality continuing medical education/continued Professional Development opportunities that will increase the knowledge, competence, and performance of health-care providers.

 

Content Areas

 

The ICI Preceptorship Program activities include practical, evidence-based, best clinical practice information for a broad variety of common oncology and hematology conditions, innovations in primary and specialty patient care in NCDs, new procedural training, and specialty fora. The appropriate content for each course is determined based on the results of a practice gap analysis relative to the target audience’s scope of practice, as well as the identified expected outcomes. Content is free of commercial bias.

 

General Target Audience: ICI Preceptorship/CME/CPD activities focus on the needs of generalist and specialist physicians and other multidisciplinary healthcare team members at ICI-affiliated cancer centers nationally and in sub-Saharan Africa as appropriate.

 

Type of Activities Provided by ICI

 

In order to accomplish our educational goals, ICI CME uses a range of activity formats based on the content and desired results of the activity. Current offerings include live and video conferenced activities, live regularly scheduled series, internet CME activities, enduring materials, and hands-on skills workshops. ICI also jointly sponsors activities with regional specialty societies, non-profit educational organizations, and government agencies when mutually desired goals and outcomes are best achieved by such relationships.

 

Expected Results of the Preceptorship Program

 

ICI Preceptorship/CME/CPD is committed to assessing the impact and effectiveness of its CME/CPD Program. ICI courses are designed to: increase knowledge of new treatments, diagnostic tools, and procedures; improve compliance with the specific evidence-based standard of care protocols; improve competence, performance, and/or patient outcomes; and promote efficient use of resources. We employ assessment methods to evaluate the extent to which our activities result in changes in knowledge, competence, and performance. CME activities in conjunction with quality improvement projects have measurable outcomes to report. An emphasis during the planning process is placed on intended learning and desired change in knowledge, competence, and performance. The ICI Education and Training Office works in collaboration with other departments/offices of the International Cancer Institute and its partners who are involved and interested in quality improvement processes and patient safety.

 

Target Audience

 

The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.

LEARNING OBJECTIVES

 

At the end of this educational activity, participants should be able to:

  1. At the end of this educational activity, participants should be able to:
  2. To learn about Multiple Myeloma outcome data in Kenya and sub-Saharan Africa (SSA)
  3. To discuss diagnostics, staging, and evaluation of a multiple myeloma patient
  4. To understand the optimal therapies, trends, research, and strategies designed to improve the quality of care in multiple myeloma including discussion on the role of Pharmacovigilance.
  5. To understand the role of the multidisciplinary team in multiple Myeloma management
  6. To understand the role of Palliative and supportive care in multiple Myeloma management
  7. Evaluate tools and resources for the management of multiple myeloma that can be used to achieve effective cancer care delivery and improve the patient experience in SSA
  8. To discuss clinical cases between faculty and participants
  9. To share experiences on How to set-up a Multiple Myeloma care program in SSA

 

Disclosure of Conflicts of Interest

 

International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

 

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

 

Disclaimer

 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Disclosure of Unlabeled Use

 

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Method of Participation and Request for Credit

 

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

 

LECTURES/COURSEWORK

 

Orientation to the course 

  1. Multiple Myeloma Data in Kenya and SSA (Chite). 
  2. Plasma Dyscrasias, Evaluation, Diagnosis and Staging of Multiple Myeloma 
  3. The Role of Pathology in Multiple Myeloma 
  4. Risk stratification, treatment of Multiple Myeloma & targeted therapies 
  5. Classification of Anti-neoplastic agents used in the treatment of Multiple Myeloma 
  6. Pharmacovigilance in the care of Multiple Myeloma patients 
  7. Role of stem-cell transplant in Multiple Myeloma 
  8. The Role of Radiotherapy in Multiple Myeloma Management 
  9. Palliative and supportive care in multiple Myeloma management 
  10. Multiple Myeloma Clinical Cases by Faculty and Participants 
  11. How to set-up a Multiple Myeloma Program in SSA (Chite)

 

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours). This program will start when the class is fully subscribed. The course cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnerships with the International Cancer Institute. Apply for sponsorship during the registration of the course

 

All those interested in registering for this course, please register your information on www.elearning.intercancer.com  if you have any questions or queries please send an email to education@intercancer.com or director@intercancer.com

 

For more information visit our website www.intercancer.com

 

International Cancer Institute (ICI) ©2022

Your Partner in Cancer Control in SSA

CMP102 MULTIPLE MYELOMA

KSh2,000.00KSh20,000.00

SKU: N/A Category: Tag:

Description

Subscribing to the course

You can purchase the entire course at Ksh. 20,000 ($200) or purchase individual units at Ksh. 2,000 ($20) per unit.

  1. Multiple Myeloma Data in Kenya and SSA
  2. Plasma Dyscrasias, Evaluation, Diagnosis and Staging of Multiple Myeloma
  3. The Role of Pathology in Multiple Myeloma
  4. Risk stratification, treatment of Multiple Myeloma & targeted therapies
  5. Classification of Anti-neoplastic agents used in the treatment of Multiple Myeloma
  6. Pharmacovigilance in the care of Multiple Myeloma patients
  7. Role of stem-cell transplant in Multiple Myeloma
  8. The Role of Radiotherapy in Multiple Myeloma Management
  9. Palliative and supportive care in multiple Myeloma management
  10. Multiple Myeloma Clinical Cases by Faculty and Participants
  11. How to set-up a Multiple Myeloma Program in SSA

Additional information

CMP

Multiple Myeloma Data in Kenya and SSA, Plasma Dyscrasias, Evaluation, Diagnosis and Staging of Multiple Myeloma, The Role of Pathology in Multiple Myeloma, Risk stratification, treatment of Multiple Myeloma & targeted therapies, Classification of Anti-neoplastic agents used in the treatment of Multiple Myeloma, Pharmacovigilance in the care of Multiple Myeloma patients, Role of stem-cell transplant in Multiple Myeloma, The Role of Radiotherapy in Multiple Myeloma Management, Palliative and supportive care in multiple Myeloma management, Multiple Myeloma Clinical Cases by Faculty and Participants, How to set-up a Multiple Myeloma Program in SSA, FULL COURSE

International Cancer Institute